EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Radiologische Responsebeurteilung moderner Immuntherapien mithilfe von iRECIST

T Persigehl, T D Poeppel, O Sedlaczek

Der Radiologe · 2017-10 · 57 (10) · 826-833

DOI: 10.1007/s00117-017-0289-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Der Radiologe, online erschienen am 15.08.2017. Verfasst von T Persigehl und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institut für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Köln, Kerpener Str. 62, 50937, Köln, Deutschland. thorsten.persigehl…. Hauptthemen laut MEDLINE: Immunotherapy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CLINICAL/METHODICAL ISSUE: Modern immunotherapies in oncology show tumor response patterns differing from conventional chemotherapies including initial pseudo-progression. STANDARD RADIOLOGICAL METHODS: Response evaluation criteria in solid tumors (RECIST 1.1) represent the currently most used response criteria for conventional chemotherapy of solid tumors. However, atypical response patterns of immunotherapies are not correctly classified using RECIST 1.1 so that the effectiveness is also incorrectly interpreted. METHODICAL INNOVATIONS: In order to correctly interpret these atypical response patterns, special immune-related response criteria in solid tumors (iRECIST) have been published. In contrast to RECIST 1.1 according to iRECIST an initially unconfirmed progressive disease (iUPD) requires confirmation (iCPD) in clinically stable patients by subsequent control imaging after 4-8 weeks. New lesions are separately assessed within iRECIST. PERFORMANCE: The iRECIST procedure allows a standardized objective assessment of a possible pseudo-progression which can occur in up to 10% of cases depending on the immunomodulating drug and tumor entity. ACHIEVEMENTS: In principle, iRECIST was developed only for usage in trials testing modern immunotherapeutics. PRACTICAL RECOMMENDATIONS: The iRECIST procedure might also be helpful as an additional objective response criterium for clinical treatment decisions, taking the limitations into account.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyHumansNeoplasmsResponse Evaluation Criteria in Solid TumorsTreatment Outcome

Stichwörter der Autor:innen

LimitationsResponse criteriaResponse patternsTreatment monitoringTumor progression

Autor:innen und Institutionen

  • Institut für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Köln, Kerpener Str. 62, 50937, Köln, Deutschland. thorsten.persigehl@uk-koeln.de.
  • Klinik für Nuklearmedizin, Universitätsklinikum Essen, Hufelandstr. 55, 45122, Essen, Deutschland.
  • Abteilung Diagnostische und Interventionelle Radiologie, NCT Heidelberg (DKFZ & Universitätsklinikum HD), Im Neuenheimer Feld 460, 69120, Heidelberg, Deutschland.

Zitieren

APA

Persigehl, T., Poeppel, T. D., & Sedlaczek, O. (2017). Radiologische Responsebeurteilung moderner Immuntherapien mithilfe von iRECIST. Der Radiologe, 57(10), 826-833. https://doi.org/10.1007/s00117-017-0289-9

Vancouver

Persigehl T, Poeppel TD, Sedlaczek O. Radiologische Responsebeurteilung moderner Immuntherapien mithilfe von iRECIST. Der Radiologe. 2017;57(10):826-833. doi:10.1007/s00117-017-0289-9

BibTeX
@article{Persigehl2017,
  author = {Persigehl, T and Poeppel, T D and Sedlaczek, O},
  title = {Radiologische Responsebeurteilung moderner Immuntherapien mithilfe von iRECIST},
  journal = {Der Radiologe},
  year = {2017},
  volume = {57},
  number = {10},
  pages = {826--833},
  doi = {10.1007/s00117-017-0289-9}
}
Kostenlos starten →